Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/ledipasvir in treatment-experienced cirrhotic adults with chronic genotype 1 hepatitis C
2013-002296-17Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing Sofosbuvir/ledipasvir + ribavirin for 12 weeks with Sofosbuvir/ledipasvir for 24 weeks (2 arms). Primary endpoint: SVR12. Started Jun 2015; status: completed.
02
Drugs
ledipasvirsofosbuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2013-002296-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002296-17.